Title:	The Managed Care Review Board - Analysis of Current and Emerging Therapies for Insomnia Web Activity
Topic:	Medical Education
Relevant Terms:	Circadian Rhythmicity, Insomnia, Managed Care, Managed-Care Pharmacy, Sleep Depervation, Sleep Disorders, Sleep Medicine
Primary Audience:	Managed Care: Medical Directors, Pharmacists, Pharmacy Directors, physicians, Registered Nurses
Launch Date:	26-Nov-13
Credits:	1.5 AMA PRA Category 1 Credits™ 1.5 ACPE contact hours 1.5 ANCC contact hours
Expiration Date:	30-Jun-15
Curriculum Name:	The Managed Care Review Board™ – Analysis of Current and Emerging Therapies for Insomnia...

Enter this activity!

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

Use knowledge of the underlying pathophysiology of sleep and wake behavior to recommend optimal treatments for patients with insomnia
Explain new scientific approaches to regulate sleep and wake behavior through the circadian rhythmicity of signaling systems in the central nervous system
Evaluate recent clinical studies on novel approaches for treating insomnia that selectively target newly discovered systems
Outline the direct and indirect costs related to insomnia as a leading cause of absenteeism, accidents, and errors in the workplace
Apply benefit design methodologies that MCOs can implement to improve the overall value for the treatment of insomnia
Provide accurate and appropriate counsel as part of the treatment team
Provide appropriate care and counsel for patients and their families

Faculty

Albert Tzeel, MD, MHSA
Regional Medical Director, Senior Products
Humana, Inc.

Albert Tzeel, MD, MHSA Albert Tzeel, MD, MHSA, FACPE is currently the Regional Medical Director of Senior Products for Humana, Inc. He most recently served as the National Medical Director for HumanaOne, based in Milwaukee, Wisconsin. Dr. Tzeel functioned as a member of the executive management team for the Individual Health Insurance Product. He provided clinical input and expertise to the development, implementation and actions of underwriting as well as strategic marketing of healthier risks. In addition, Dr. Tzeel created clinical strategies coordinated with other clinical management processes in place throughout the Company. Specifically, he functioned as the internal subject matter expert on the topic of diabetes. Prior to his assuming the role with HumanaOne, Dr. Tzeel was the Regional Market Medical Officer for Humana's Wisconsin and Michigan markets. He is a Board Certified pediatrician.

Dr. Tzeel joined Humana in March, 1999 as Medical Director for the Milwaukee market. Previously, he served as Associate Medical Director for the Health Alliance Plan in Detroit, Michigan. Dr. Tzeel earned his Medical Degree from the University of Michigan Medical School in Ann Arbor, MI and his Masters in Health Services Administration from the University of Michigan School of Public Health, also in Ann Arbor. He is a Certified Physician Executive, a Fellow of the American College of Physician Executives and a Fellow of the American Academy of Pediatrics.

Dr. Tzeel represents Humana on numerous external committees including the Board of Directors of the Center for Health Value Innovation (www.vbhealth.org) and the Board of Advisors for the Wisconsin Health Information Exchange (www.whie.org). He had also been appointed to the Governance Committee of the Wisconsin Relay of Electronic Data (WIRED) for Health Board. Earlier, he served as the Chair of the Healthcare subcommittee of the Wisconsin Partnership on Activity and Nutrition. Dr. Tzeel is the author or co-author of multiple papers and books including "When to Call the Doctor" (Dalmatian Press, 1999) and "The Encyclopedia of Children's Health and Wellness" (Facts on File, 2004).

Carl V. Asche, PhD
Director and Research Professor
Center for Outcomes Research
University of Illinois College of Medicine at Peoria

James Kenney, Jr., RPh, MBA
Pharmacy Operations Manager
Harvard Pilgrim Healthcare, Inc.

Andrew Krystal, MD, MS
Director of the Insomnia and Sleep Research Program
Duke University School of Medicine

Jointly sponsored/co-provided by the Postgraduate Institute for Medicine and Impact Education, LLC

www.impactedu.net www.pimed.com

The Managed Care Review Board™ – Analysis of Current and Emerging Therapies for Insomnia Web Activity

Supported by an educational grant from Merck & Co., Inc.

Estimated time to complete activity: 1.5 hours

Target Audience

Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for insomnia including: physicians, pharmacists, registered nurses, and case managers

Statement of Need
Insomnia is a leading cause of absenteeism, accidents, and errors in the workplace. Overall direct and indirect costs related to insomnia exceed $30 billion annually. A significant portion of these costs are attributable to patients with conditions comorbid to insomnia, which include mood and anxiety disorders; chronic pain; respiratory, urinary, and neurologic conditions; diabetes mellitus; and cardiovascular disease.

Through the use of new genetic tools, researchers are rapidly developing a better understanding of the basic science underlying sleep and wake behavior. Novel approaches that selectively target newly discovered systems related to insomnia have demonstrated efficacy in clinical studies. Some of these new approaches regulate sleep and wake behavior by taking advantage of the circadian rhythmicity of specific signaling systems in the central nervous system (CNS).

Because of the large volume of patients they manage, MCOs and other payers are in an excellent position to improve outcomes for patients with insomnia. By enhancing their knowledge of emerging science, pathophysiology, and emerging agents and by improving coordination of care, managed care professionals can reduce the health care burden associated with insomnia.

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacist Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – 0809-9999-13-344-H01-P)

Type of Activity: Application

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Nursing Continuing Education

Nursing Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Nursing Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Reported Financial Relationship
Carl V. Asche, PhD	Consulting Fees: Novo Nordisk, Astellas, Bayer
James Kenney, Jr., RPh, MBA	No financial interest/relationships relating to the topic of this activity
Andrew Krystal, MD, MS	Consulting Fees: Abbott, Astellas, AstraZeneca, BMS, Teva/Cephalon, Eisai, Eli Lilly, GlaxoSmithKline, Jazz, Johnson and Johnson, Merck, Neurocrine, Novartis, Ortho-McNeil-Janssen, Respironics, Roche, Sanofi-Aventis, Somnus, Sunovion/Sepracor, Somaxon, Takeda, Transcept, Kingsdown Inc. Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: NIH, Teva/Cephalon, Pfizer, Sunovion/Sepracor, Transcept, Phillips-Respironics, Astellas, Abbott, Neosynch, Brainsway
Albert Tzeel, MD, MHSA	Salary: Humana Consulting Fees: Amylin Ownership Interest: Humana

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Steven Casebeer, MBA

Has nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period November 26, 2013 through June 30, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the embedded questions within the activity; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Media
Internet

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

Fee Information
There is no fee for this educational activity.

Questions
If you have any questions, please call (215) 619-8812 or email MCRB@impactedu.net

Select button below to begin the activity.

Enter this activity!

The Managed Care Review Board - Analysis of Current and Emerging Therapies for Insomnia Web Activity

Learning Objectives

Faculty